{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:54:37Z","timestamp":1782435277331,"version":"3.54.5"},"reference-count":49,"publisher":"Informa UK Limited","issue":"13","license":[{"start":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T00:00:00Z","timestamp":1631145600000},"content-version":"unspecified","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"not funded"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2021,9,2]]},"DOI":"10.1080\/14656566.2021.1942455","type":"journal-article","created":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T08:49:19Z","timestamp":1629276559000},"page":"1651-1660","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":19,"title":["Evaluating pimavanserin as a treatment for psychiatric disorders: A pharmacological property in search of an indication"],"prefix":"10.1080","volume":"22","author":[{"given":"John","family":"Davis","sequence":"first","affiliation":[{"name":"School of Public Health\/Psychiatric Institute (SPHPI), University of Illinois-Chicago, Chicago"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisy","family":"Zamora","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of North Carolina-Chapel Hill, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Horowitz","sequence":"additional","affiliation":[{"name":"School of Public Health\/Psychiatric Institute (SPHPI), University of Illinois-Chicago, Chicago"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[{"name":"Deputy Director Department of Psychiatry and Psychotherapy, Technical University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,8,18]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.105.097006"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2016.11.013"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.03.020"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1007\/s11064-014-1293-3"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2020.05.004"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2009.176"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31135-3"},{"key":"cit0008","unstructured":"NUPLAZID (pimavanserin) tablets, for oral use. [Package insert] April 2016 [cited; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/207318lbl.pdf"},{"key":"cit0009","author":"Kremens DE.","year":"2016","journal-title":"Am J Manag Care"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62106-6"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2010.35"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.2217\/nmt-2018-0039"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23083"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852916000407"},{"key":"cit0015","unstructured":"ClinicalTrials.gov. Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer\u2019s Disease (SERENE).Mar.28.2019.ed. Bethesda, MD: National Library of Medicine 2019."},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852920001765"},{"issue":"4","key":"cit0017","first-page":"253","volume":"5","author":"Cummings J","year":"2018","journal-title":"J Prev Alzheimers Dis"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30039-5"},{"key":"cit0019","doi-asserted-by":"crossref","unstructured":"Foff EP, Cummings J, M-e S-M, et al. HARMONY Study: pimavanserin Significantly Reduces Risk of Relapse of Dementia-Related Psychosis.Gerontological Advanced Practice Nurses Association. Virtual. 2020.","DOI":"10.1017\/S104161022000280X"},{"key":"cit0020","volume-title":"FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis","author":"Acadia Pharmaceuticals Receives Complete Response Letter from U.S","year":"2021"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19m12928"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000328"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2020.08.051"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1002\/da.23017"},{"key":"cit0025","unstructured":"ACADIA Pharmaceuticals Announces. Top-line Results from the Phase 3 CLARITY Study Evaluating Pimavanserin for the Adjunctive Treatment of Major Depressive Disorder. 2020. Acadia Pharmaceuticals Inc."},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2012.07.029"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2019.02.018"},{"key":"cit0028","volume-title":"Congress of the Schizophrenia International Research Society","author":"Bugarski-Kirola D","year":"2020"},{"key":"cit0029","unstructured":"ClinicalTrials.gov. Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE).Dec.Vol. 22.2020.Bethesda, MD:National Library of Medicine."},{"key":"cit0030","volume-title":"American College of Neuropsychopharmacolgy Annual Meeting","author":"Bugarski-Kirola D","year":"2019"},{"key":"cit0031","unstructured":"ClinicalTrials.gov. Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1).Jun.Vol. 17.2020.Bethesda, MD:National Library of Medicine."},{"key":"cit0032","volume-title":"Congress of the Schizophrenia International Research Society","author":"Bugarski-Kirola D","year":"2020"},{"key":"cit0033","unstructured":"FDA analysis finds no new or unexpected safety risks associated with Nuplazid (pimavanserin), a medication to treat the hallucinations and delusions of Parkinson\u2019s disease psychosis. Drug Safety and Availability.2018.September.20.cited 2020 Dec 30.Available from:https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-analysis-finds-no-new-or-unexpected-safety-risks-associated-nuplazid-pimavanserin-medication"},{"key":"cit0034","unstructured":"ClinicalTrials.gov. A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson\u2019s Disease Psychosis. May 17, 2017 [cited Jun 3, 2021 Available from:https:\/\/www.clinicaltrials.gov\/ct2\/show\/results\/NCT00477672"},{"key":"cit0035","unstructured":"ClinicalTrials.gov. A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson\u2019s Disease Psychosis. May 19, 2017 [cited Jun 3, 2021 Available from:https:\/\/www.clinicaltrials.gov\/ct2\/show\/results\/NCT00658567"},{"key":"cit0036","unstructured":"ClinicalTrials.gov. A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson\u2019s Disease Psychosis. Mar 26, 2014 [cited Jun 3, 2021 Available from:https:\/\/www.clinicaltrials.gov\/ct2\/show\/results\/NCT01174004"},{"issue":"5","key":"cit0037","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/jnc.15269","volume":"156","author":"Grunder G","year":"2021","journal-title":"J Neurochem"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2019.10.013"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.24244"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1016\/bs.irn.2020.03.024"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1186\/s12979-017-0108-1"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105283"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1038\/nature06612"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032994"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2020.3285"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2015.00225"},{"key":"cit0047","first-page":"27","volume":"2018","author":"Sommer IEC","year":"2018","journal-title":"BMJ Case Rep"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00591"},{"key":"cit0049","volume-title":"ClinicalTrials.gov. The Sub-Sero Study","volume":"26","year":"2019"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2021.1942455","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T15:01:36Z","timestamp":1673103696000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2021.1942455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,18]]},"references-count":49,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2021,9,2]]}},"alternative-id":["10.1080\/14656566.2021.1942455"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2021.1942455","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,18]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-03-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}